Peritoneal carcinomatosis: Cytoreductive surgery and HIPEC-overview and basics

Cancer Investigation

Volumn 30, Issue 3, 2012, Pages 209-224

  Brcher, Björn L D M ^a   Piso, Pompiliu ^b   Verwaal, Vic ^c   Esquivel, Jesus ^d   Derraco, Marcello ^e   Yonemura, Yutaka ^f   Gonzalez Moreno, Santiago ^g   Pelz, Jörg ^h   Königsrainer, Alfred ^a   Ströhlein, Michael ⁱ   Levine, Edward A ^j   Morris, David ^k   Bartlett, David ^l   Glehen, Olivier ^m   Garofalo, Alfredo ⁿ   Nissan, Aviram ^o  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d ST AGNES HOSPITAL   (United States)

^e Institution Nationali Tumori   (Italy)

^f NPO Organization to Support Peritoneal Dissemination Treatment   (Japan)

^g MD ANDERSON CANCER CENTER   (Spain)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ UNIVERSITY OF WITTEN HERDECKE   (Germany)

^j WAKE FOREST SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m UNIVERSITÉ LYON 1   (France)

ⁿ Institutio Nazionale Tumori Regina ^*  (Italy)

^o RABIN MEDICAL CENTER   (Israel)

more..

Author keywords

Colon cancer; Gastric cancer; HIPEC; Peritoneal carcinomatosis; Pseudomyxoma

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; OXALIPLATIN;

ABDOMINAL SURGERY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CARDIOTOXICITY; CC SCORE; CHOLECYSTECTOMY; COLORECTAL CARCINOMA; COLORECTAL SURGERY; COLORECTAL TUMOR; CYTOREDUCTIVE SURGERY; DISSECTION; GASTRECTOMY; GILLY CLASSIFICATION; HISTOPATHOLOGY; HUMAN; HYPERTHERMIA; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; INTRAOPERATIVE PERIOD; LAPAROSCOPY; LIVER RESECTION; MINIMAL RESIDUAL DISEASE; MORBIDITY; MULTIMODALITY CANCER THERAPY; NONHUMAN; OMENTECTOMY; OVARY CARCINOMA; P SCORE; PATIENT POSITIONING; PERITONECTOMY; PERITONEUM MESOTHELIOMA; PERITONEUM PSEUDOMYXOMA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SMALL INTESTINE RESECTION; SPLENECTOMY; STOMACH CARCINOMA; SUGARBAKER PERITONEAL CARCINOMATOSIS INDEX; SURGICAL MORTALITY; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; UROLOGIC SURGERY; VERWAAL N SCORE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; LAPAROSCOPY; PERITONEAL NEOPLASMS; PERITONEUM; PROGNOSIS;

EID: 84857586698     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.654871     Document Type: Review

References (97)

1. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221(1):29-42.
2. BeaujardAC, GlehenO, Caillot JL, Francois Y, Bienvenu J, Panteix G, Garbit F, Grandcl ́ement E, Vignal J, Gilly FN. Intraperitoneal chemohyperhermia with mytomycin C for digestive tract patients with peritoneal carcinomatosis. Cancer 2000;88(11):2512-2519. (Pubitemid 30331957)
3. Gilly FN, Beaujard A, Glehen O, Grandclement E, Caillot JL, Francois Y, Sadeghi-Looyeh B, Gueugniaud PY, Garbit F, Benoit M, Bienvenu J, Vignal J. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study. Anticancer Res 1999;19(3B):2317-2321. (Pubitemid 29392542)
4. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85(3):529-534. (Pubitemid 29075274)
5. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43(Suppl):S15-S25. (Pubitemid 29244628)
6. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In Peritoneal Carcinomatosis: Principles of Management, PH Sugarbaker (ed). Boston: Kluwer, 1996, 79-100.
7. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88(2):358-363. (Pubitemid 30051820)
8. Baron MA. Structure of the intestinal peritoneum in man. Am J Anat 1941;69:439-497.
9. Sugarbaker PH. Peritoneum as the first line of defense in carcinomatosis. J Surg Oncol 2007;95:93-96. (Pubitemid 46238975)
10. Konigsrainer I, Zieker D, Beckert S, vonWeyhern C, L̈ob S, Falch C, Br̈ucher BLDM, Konigsrainer A, Glatzle J. Influence of local peritonectomy on recurrence in colorectal cancer: An experimental study in a standardized rat model. Cell Physiol Biochem 2009;23:371-378.
11. Stelin G, Rippe B. A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD. Kidney Int 1990;38:465-472. (Pubitemid 20258749)
12. Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon.World J Surg 1996;5:585-591.
13. Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T.Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol 2006;32:602-606. (Pubitemid 44063992)
14. Gonzalez-Moreno S, Ortega-Perez G, Gonzalez-Bayon L. Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Surg Onc 2009;100:287-292.
15. Rufi ́an S, Mu&tild;noz-Casares FC, Brice&tild;no J, Diaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo M, Aranda E, Muntane J, Pera C. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006;94:316-324. (Pubitemid 44330855)
16. Br̈ucher BLDM, K̈onigsrainer A. Peritonealcarcinose. CHAZ 2010;11(1):17-31.
17. ChuDZ, LangNP,ThompsonC,Osteen PK,WestbrookKC. Peritoneal carcinomatosis in nongynecologic malignancy: A prospective study of prognostic factors. Cancer 1989;63:364-367. (Pubitemid 19035034)
18. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitonea chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28(1):63-68.
19. Sugarbaker PH. New standard of care for appendiceal epithelialmalignancies and pseudomyxoma peritonei syndrome. Lancet Oncol 2006;7:69-76. (Pubitemid 43025395)
20. Konigsrainer I, Beckert S, Lehmann T, Ladurner R, Br̈ucher BLDM, Konigsrainer A. Peritoneal carcinomatosis. Chirurg 2011;82(4):375-380.
21. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49-58. (Pubitemid 26130826)
22. Verwaal VJ, Van Tinteren H, Van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739-746. (Pubitemid 38746143)
23. Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, Bienvenu J, Burgard G, Guibert B, Banssillon V, Braillon G. Regional chemotherapy and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis.Hepatogastroenterology 1994;41:124-129. (Pubitemid 24140784)
24. Kajitani T (Japanese Research Society for Gastric Cancer). The general rules for the gastric cancer study in surgery and pathology: part I. Clinical classification. Jpn J Surg 1981;11:127-139. (Pubitemid 11080134)
25. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, AlexanderR, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha- Boix P, Chang CK, Chu F, Chu Q, Daniel S, deBree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez- Moreno S,GoodmanM, GushchinV, HannaN,HartmannJ,Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, La- Mont J, Lange J, Li B, Loggie B, Mahteme H,Mann G,Martin R, MisihRA,MoranB,MorrisD,Onate-OcanaL,PetrelliN, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, RutsteinL, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128-133. (Pubitemid 44954279)
26. Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Onc 2009;100:321-328.
27. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am 2003;12:703-727. (Pubitemid 36920094)
28. Vazquez V de L, Sugarbaker PH.Total anterior parietal peritonectomy. J Surg Oncol 2003;83:261-263. (Pubitemid 36936013)
29. Ozel L, Ozel MS, Toros AB, Kara M, Ozkan KS, Tellioglu G, Krand O, Koyuturk M, Berber I. Effect of early preoperative 5- fluorouracil on the integrity of colonic anastomoses in rats.World J Gastroenterol 2009 15(33):4156-4162.
30. Pelz JO,Doerfer J,Decker M, DimmlerA,Hohenberger W,Meyer T. Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model. Int J Colorectal Dis 2007;22:941-947. (Pubitemid 46952043)
31. Van der Speeten K, Stuart OA, Sugarbaker PH. Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol 2009;6:72-81.
32. Dedrick RL,Myers CE, Bungay PM,DeVitaVT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-11. (Pubitemid 8278518)
33. Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ,Mullins RE, Hull WE, Oliff L, Schlag P. Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patientswith advanced gastrointestinal cancer. Cancer Res 1990;50:5790-5794. (Pubitemid 20331378)
34. Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005;10:112-122. (Pubitemid 40261950)
35. Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia 2005;21:681-687. (Pubitemid 41807093)
36. Kusumoto T,Holden SA, Teicher BA.Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia 1995;11:575-586.
37. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980;40:1165-1168. (Pubitemid 10135826)
38. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998;41:147-154. (Pubitemid 28096269)
39. Sugarbaker PH,ChangD. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727-731. (Pubitemid 30013648)
40. Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G, Beaujard AC, Noel GF. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Onc 2008;98:242-246.
41. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a high morbid procedure? Ann Surg 2009;249:900-907.
42. Gonzalez-Moreno S, Kusamura S, Baratti D, Deraco M. Postoperative residual disease evaluation in the locoreginal treatment of peritoneal surface malignancy. J Surg Onc 2008;98:237-241.
43. Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. EJSO 2006;32:625-627. (Pubitemid 44064002)
44. Garofalo A, Valle M. Laparoscopy in the management of peritoneal carcinomatosis. Cancer J 2009;15(3):190-195.
45. Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multiinstitutional retrospective analysis in 52 patients. J Surg Onc 2009;100:331-334.
46. Laterza B, Kusamura S, Baratti D, Olivia GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo 2009;23:187-190.
47. YonemuraY, Endou Y, ShinboM, Sasaki T, HiranoM, Mizumoto A, Matsuda H, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, Miura M, Ikeda M, Ikeda S, Nakajima G, Nonemura J, Yuuba T, Masuda S, Kimura H, Matsuki N. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination fromgastric cancer: selection for cytoreductive surgery. J Surg Onc 2009;100:311-316.
48. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739-746. (Pubitemid 38746143)
49. Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using coliseum technique. Ann urg Oncol 1999;6:790-796. (Pubitemid 30013658)
50. Saxena A, Yan TD, Morris DL. A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 2010;34:70-78.
51. Saxena A, Chua TC, Yan TD, Morris DL. Postoperative pancreatic fistula after cytoreductive surgery and perioperative intraperitoneal chemotherapy: Incidence, risk factors, management and clinical sequelae. Ann Surg Oncol 2010;17(5):1302-1310.
52. Kerscher AG, Mallalieu J, Pitroff A, Kerscher F, Esquivel J. Morbidity and mortality of 109 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC) performed at a community hospital.Worl J Surg 2010;34:62-69.
53. Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, Francois Y, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: orbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10(8):863-869. (Pubitemid 40486849)
54. Piso P, Slowik P, Popp F, Dahlke MH, Glockzin G, Schlitt HJ. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2009;16:2188-2194.
55. Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20-26. (Pubitemid 38049613)
56. Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113(6):631-636. (Pubitemid 23176305)
57. Kusamura S,Younan R, Baratti D, Costanzo P, FavaroM, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006;106(5):1144-1153.
58. Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004;85(2):61-67. (Pubitemid 38160772)
59. Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, Zeh HJ, Bartlett DL. Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol 2008;15(11):3065-3072.
60. Moradi BN, Esquivel J. Learning curve in cytoreductive surgery and hyperthermic intraperiotneal chemotherapy. J Surg Onc 2009;100:293-296.
61. GusaniNJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high volume tertiary cancer center. Ann Surg Oncol 2007;15(3):754-763.
62. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28(1):63-68.
63. Capone E,ValleM, Proietti F, FedericiO,GarofaloA, PetrosilloN. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Onc 2007;96:507-513. (Pubitemid 350044395)
64. Ronett BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997;2:197-226.
65. Carmignani CP, Sugarbaker TA, BromleyCM, Sugarbaker PH. Intraperitoneal cancer dissemination:mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465-472. (Pubitemid 36791900)
66. Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J SurgOncol 2007;96:102-112. (Pubitemid 47264812)
67. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2010;17:45-53.
68. Sugarbaker PH. Patient selection and treatment of peritoneal carcinomatosis fromcolorectal and appendiceal cancer.World J Surg 1995;19:235-240.
69. Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, Dalton RR, Eltinghausen SE, Jacquet P, Jelinek J, Koslowe P, Kurman RJ, Shmookler B, Stephens AD, Steves MA, Stuart OA, White S, Zahn CM, Zoetmulder FA. Pseudomyxoma peritonei. Adv Surg 1997;30:233-280.
70. Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Lab Med 2006;130:1654-1661. (Pubitemid 44683793)
71. Deraco M,De Simone M, Rossi CR, Cavaliere F,Difilippo F, Scuderi S, Pilatti P, Kusamura S. An Italian multicentric phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res 2003 22(4 Suppl):41-45. (Pubitemid 38436432)
72. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohammed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritonealmesothelioma: multi-institutional experience. J Clin Oncol 2009;27(3):6237-6242.
73. Tentes AA, Tirpsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, Avgidou K. Peritoneal cancer index: A prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003;29:69-73. (Pubitemid 36181781)
74. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003;13:764-770. (Pubitemid 38235220)
75. Mu&tild;noz-Casares FC, Rufi ́an S, Rubio MJ, D ́iaz CJ, D ́iaz R, Casado A, Arjona A, Mu&tild;noz-Villanueva MC, Muntan ́e J. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol 2009;11(11):753-759.
76. Cotte E, Glehen O, Mohammed, Lamy F, Falandry C, Golfier F, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 2007;31:1813-1820. (Pubitemid 47283201)
77. Okajima K, Yamada S. Surgical treatment of far-advanced gastric cancer. Jpn J Cancer Clin 1986;32:1203-1209.
78. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000;58:96-107. (Pubitemid 30113860)
79. ChuDZ, LangNP,ThompsonC,Osteen PK,WestbrookKC. Peritoneal carcinomatosis in nongynecologic malignancy: A prospective study of prognostic factors. Cancer 1989;63:364-367. (Pubitemid 19035034)
80. Yamada S, Takeda T, Matsumoto K. Prognostic analysis of malignant pleural and peritoneal effusions. Cancer 1983;51:136-140. (Pubitemid 13169588)
81. Yonemura Y, Kawamura T, Bandou E, Takahasi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination fromgastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370-375. (Pubitemid 40445602)
82. Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20-26. (Pubitemid 38049613)
83. Hall JJ,LoggieBW, ShenP, Beamer S, DouglasCaseL,McQuellon R,GeisingerKR, Levine EA.Cytoreductive surgerywith intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454-463. (Pubitemid 38561210)
84. Bozzetti F, Yu W, Baratti D, Kusamura S, DeracoM. Locoregional treatment of peritoneal carcinomatosis fromgastric cancer. J Surg Oncol 2008 98(4):273-276.
85. Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M, Yonemura Y, Baba H. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009;250(2):242-246.
86. Pfannenberg C, Konigsrainer I, Aschoff P, ̈ Oks̈uz M, Zieker D, Beckert S, Symons S, Nieselt K, Glatzle J, Br̈ucher BLDM, Claussen CD, Konigsrainer A. 18F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2009;16(5):1295-1303.
87. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739-746. (Pubitemid 38746143)
88. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8- year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426-2432.
89. Li PC, Chen LD, Zheng F, Li Y. Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: Results of an experimental study. J Cancer Res Clin Oncol 2008;134:37-44. (Pubitemid 350060682)
90. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
91. Loges S,Mazzone M,Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 2009;15:167-170.
92. P̀aez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinalis F, InoueM, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231
93. Glasziou P, Chalmers I, Rawlins M, McCulloch P.When are randomized trials unnecessary? Picking signal from the noise. Brit Med J 2007;334(7589):349-351. (Pubitemid 46328045)
94. Nissan A, Stojadinovic A, Garofalo A, Esquivel J, Piso P. Evidencebased medicine in the treatment of peritoneal carcinomatosis: Ast, present, future. J Surg Onc 2009;100:335-344.
95. Chua TC, Martin S, Cert G, Saxena A, Liauw W, Yan TD, Zhao J, Lok I, Cert G, Morris DL. Evaluation of the costeffectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. Ann Surg 2010;251(2):323-329.
96. Wagner BJ, L̈ob S, Lindau D,ḦorzerH, G̈uckel B, Klein G, Glatzle J, Rammensee HG, Br̈ucher BLDM, Konigsrainer A. Simvastatin reduced tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and ß1 integrin. Int J Oncol 2011;39(6):1593-1600.
97. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a high morbid procedure? Ann Surg 2009;249:900-907.